693 related articles for article (PubMed ID: 33271264)
1. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
4. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
6. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
8. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
9. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
10. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
11. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
12. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
13. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.
Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L
Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
[TBL] [Abstract][Full Text] [Related]
16. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
17. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
18. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
[TBL] [Abstract][Full Text] [Related]
20. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]